May 24 | 2022
2cureX publishes interim report for the first quarter 2022
Read more
May 20 | 2022
We invite you to join the 2cureX Q1 Report webcast and Q&A session at 15:00 on 24 May, 2022
Read more
May 17 | 2022
Three IndiTreat® posters have been accepted at ESMO-GI 2022
Read more
May 12 | 2022
2cureX AB nominates Dr. Michael Schaefer to the Board of Directors
Read more
May 11 | 2022
IGNITE update – Eight hospitals have been enrolled in the program
Read more
May 9 | 2022
2cureX presents IndiTreat® clinical results at the Society for Functional Precision Medicine
Read more
May 6 | 2022
2cureX appoints Sedermera Corporate Finance AB to act as a liquidity provider for the Company´s share
Read more
May 5 | 2022
Redeye research interview with 2cureX CEO, Fernando Andreu
Read more
May 3 | 2022
2cureX publishes the annual report for the fiscal year 2021
Read more
April 22 | 2022
Correction of “Notice of annual general meeting of 2cureX AB (publ)” issued on 21st April 2022
Read more
April 21 | 2022
Notice of annual general meeting of 2cureX AB (publ)
Read more
April 21 | 2022
Manuel Fernández joins 2cureX as Director of Quality Assurance and Regulatory Affairs.
Read more
April 14 | 2022
Chairman of the 2cureX Board exercises all warrants within the framework of the 2018 incentive program
Read more
March 15 | 2022
Mangold Fondkommission AB published an updated Analyst Report on 2cureX
Read more
March 14 | 2022
2cureX launches IndiTreat® mCRC Explore and completes portfolio rollout plan for 2022
Read more
February 24 | 2022
2cureX publishes interim report for the fourth quarter and all 12 months of 2021
Read more
February 23 | 2022
2cureX holds a virtual live-session on the 25th of February 2022 to present and discuss the Interim report for the fourth quarter of 2021.
Read more
February 23 | 2022
2cureX reorganizes to an even stronger distributor focus
Read more